1. Home
  2. EVV vs ANNX Comparison

EVV vs ANNX Comparison

Compare EVV & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Limited Duration Income Fund of Beneficial Interest

EVV

Eaton Vance Limited Duration Income Fund of Beneficial Interest

HOLD

Current Price

$9.51

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.66

Market Cap

972.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVV
ANNX
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
972.5M
IPO Year
2003
2020

Fundamental Metrics

Financial Performance
Metric
EVV
ANNX
Price
$9.51
$5.66
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$16.50
AVG Volume (30 Days)
298.2K
2.0M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16,320.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.97
$1.85
52 Week High
$10.41
$7.18

Technical Indicators

Market Signals
Indicator
EVV
ANNX
Relative Strength Index (RSI) 52.02 47.00
Support Level $9.38 $4.79
Resistance Level $9.57 $6.56
Average True Range (ATR) 0.11 0.29
MACD 0.01 -0.07
Stochastic Oscillator 26.85 37.72

Price Performance

Historical Comparison
EVV
ANNX

About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest

Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: